Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Pharma Equity Group
0,174
DKK
+2,65 %
PEG
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
13 seuraajaa
+2,65%
+8,41%
−29,27%
−27,5%
−59,53%
−56,28%
−42%
−79,59%
−99,33%
Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.
Lue lisääMarkkina-arvo
213,59 milj. DKK
Vaihto
245,18 t. DKK
Liikevaihto
EBIT %
P/E -luku
Osinkotuotto %
Seuranta
Viimeisimmät analyysit
Viimeisin analyysiraportti
Julkaistu: 28.10.2024
NäytäKaikki sisältötyypit
Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S
Pharma Equity Group: Opdatering fra interview med CEO Thomas K. Selsø
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Consolidated Interim report 1 January – 30 September 2024
Pharma Equity Group (One-pager): Capital position strenghtened
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.
Major shareholder announcement - Pharma Equity Group A/S
Managers’ transactions
Pharma Equity Group announces successful completion of directed issue of new shares
Pharma Equity Group: Directed issue with premium to closing price.
Pharma Equity Group announces issuance of new shares in a direct issue
Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights
Consolidated Interim Report 1 January – 30 June 2024
The Board of Directors' decision to issue convertible loans
Major shareholder announcement - Pharma Equity Group A/S
Major shareholder announcement - Pharma Equity Group A/S
HCA Capital: Wrap up from 2024 Life Science seminar
Life Science seminar 2024
Results of extraordinary general meeting in Pharma Equity Group A/S